{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-25-000582","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2025-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.826717+00:00","generated_at":"2026-05-23T02:03:09.052567+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Immunic's vidofludimus calcium reduces disability worsening risk by 30% in PPMS from phase 2 CALLIPER trial","bullets":["Vidofludimus calcium reduced 24-week confirmed disability worsening risk by 20% overall (n=467) vs placebo.","In PPMS subgroup (n=152), risk reduced by 30%; in non-active SPMS (n=268) by 15%.","Reduced annualized thalamic brain volume loss by 20% vs placebo; T2 lesion burden improved.","Safety profile consistent with prior trials: TEAEs 69.4% (drug) vs 68.5% (placebo); SAEs 8.1% vs 6.5%.","Company plans to discuss phase 3 registration path with healthcare authorities."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-25-000582","json":"https://secwatch.observer/filing/0001193805-25-000582.json","markdown":"https://secwatch.observer/filing/0001193805-25-000582.md","text":"https://secwatch.observer/filing/0001193805-25-000582.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000582/0001193805-25-000582-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000582/e664445_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T02:03:09.052567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}